

Personal data

- Name: Sine Reker Hadrup
- Address: Kirkebakken 12, 2830 Virum
- DOB: 08/21/1975
- Orcid ID: orcid.org/0000-0002-5937-4344

Publications and patents

- 67 Peer-review publications
- 5 patents per Aug 2017
- H-index: 22
- Citations: 1566

Education

- 2006: PhD. Faculty of Health Science, University of Copenhagen.
- 2002: M.Sc. Human biology, Faculty of Health Science, University of Copenhagen.
- 1999: B.Sc. Pharmacy, The Danish University of Pharmaceutical Sciences, Copenhagen.

Current Position

- Oct 2017 - : Professor, Danish Technical University (DTU), Division for Immunology and Vaccinology, Group head (PI) of >25 group members
- 2014-2017: Associate Professor, Danish Technical University (DTU)

Former Research Experience

- 2008-2014: Group head, Center for Cancer Immune Therapy, Herlev University Hospital, Denmark.
- 2010-2012: External associate professor, University of Copenhagen
- 2006-2008: Postdoc at Netherlands Cancer Institute (NKI), Amsterdam. Dept. of Immunology.
- 2002-2005: PhD in tumor immunology performed at The Danish Cancer Society, Dept. of Tumor Cell Biology

Research Support & Awards

- The Danish Innovation fond, WP leader NeoPepVac (500.000 EUR 2017-2021)
- **ERC PoC grant** (150.000 EUR, 2017-18)
- H2020-PM-09, IMMUNOSABR, WP leader (WP budget 1M EUR 2017-2022)
- **ERC-StG**, Start June 1st 2016, (1.5 M EUR, 2016-21)
- The Danish Cancer Society, Junior researcher award, 2015 (10.000 EUR)
- **Lundbeck Foundation fellowship** (1.3 M EUR, 2015-20)
- The Danish Council for Independent Research, Medical Sciences, **SAPER AUDE** Starting grant (674.000 EUR, 2015-18)

Scientific focus areas:

I am focused on development of multiplex strategies for T cell detection to comprehensively assess antigen-specific tumor reactivity among T cells in cancer patients. Novel technologies developed in my research group allows simultaneous detection of >1000 different antigen-responding T cells. My research group is focusing on using this technology to unravel the immune reactivity towards cancer associated neo- and shared epitopes, as well as understanding the influence of cancer therapy on the immune recognition fingerprint in individual patients.